Navigation Links
PharmAthene Reports Third Quarter 2011 Financial and Operating Results
Date:11/9/2011

ceivables, net (including unbilled receivables)2,343,9874,317,170Prepaid expenses and other current assets470,6661,014,002Assets held for sale976,6001,000,100Total current assets18,337,03023,583,729Property and equipment, net900,9261,178,416Other long-term assets and deferred costs53,38488,447Goodwill2,348,4532,348,453Total assets$

21,639,793$

27,199,045LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable$

445,515$

3,128,203Accrued expenses and other liabilities3,245,9903,035,284Total current liabilities3,691,5056,163,487Other long-term liabilities454,093461,858Derivative instruments2,956,0808,362,995Total liabilities7,101,67814,988,340Stockholders' equity:Common stock, $0.0001 par value; 100,000,000 shares authorized; 48,194,035 and 46,238,244 shares issued and outstanding at September 30, 2011 and December 31, 2010, respectively4,8194,624Additional paid-in-capital207,810,326200,847,468Accumulated other comprehensive income1,161,6201,250,497Accumulated deficit(194,438,650)(189,891,884)Total stockholders'
equity14,538,11512,210,705Total liabilities and stockholders' equity$

21,639,793$

27,199,045PHARMATHENE, INC.UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSThree months endedSeptember 30,Nine months endedSeptember 30,2011201020112010Contract revenue$

5,260,057$

6,243,567$

18,026,619$

14,139,711Operating expenses:Research and development4,884,2316,172,14716,688,70317,064,900General and administrative3,283,2463,177,88811,632,27212,625,132Depreciation and amortization114,494258,231348,813757,929Total operating expenses8,281,9719,608,26628,669,78830,447,961Loss from operations(3,021,914)(3,364,699)(10,643,169)(16,308,250)Other income (expenses):Interest income3,96118410,4966,249Interest expense(9,932)(946,023)(40,540)(2,815,638)Other income (expense)95,520(93,260)50,89275,914Change in market value of derivative instruments2,898,86975,5946
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
2. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
3. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
4. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
5. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
6. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
7. PharmAthene Completes $6.5 Million Registered Direct Offering
8. PharmAthene Reports First Quarter 2011 Financial and Operating Results
9. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
10. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
11. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... LOUIS , Dec. 23, 2014 ... today that the waiting period under the Hart-Scott-Rodino ... the acquisition expired on December 22, 2014, thereby ... review requirement for the acquisition of the Company ... U.S. antitrust clearance satisfies another condition to closing ...
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
(Date:12/22/2014)... 2014  ( www.competitivehealth.com ) — Competitive Health is ... review and advocacy service, has signed an agreement to ... discount health services marketplace. 63% of Americans ... they expected to pay. As part of an ongoing ... Savings is pleased to offer medical bill review and ...
(Date:12/19/2014)... 19, 2014 Bioject Medical Technologies ... manufacturer of needle-free injection technology, today announced that ... Therapeutics, Inc. (“ITI”) for ITI to use the ... LAMP™ vaccine platform. , In the agreement, ... license to the Biojector®-2000 that triggers based on ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... MONTREUX, Switzerland, Feb. 4 Patients with frequently,relapsing ... time to an,initial relapse when risperidone long-acting injection ... new study. The study compared,patients who received RLAI ... combined with placebo., The study was presented ...
... CARLSBAD, Calif., Feb. 4 Ardea Biosciences,Inc. (Nasdaq: ... virus (HIV) Scientific Advisory Board (SAB) with the,appointment of ... SAB will,provide independent scientific advice and counsel to the ... to treat HIV., "Establishing a strong scientific advisory ...
... MINNEAPOLIS, Feb. 4 Uroplasty, Inc. (Amex:,UPI) announced ... the third,quarter of fiscal 2008 ended December 31, ... 2008. The Company will host a conference call ... at 10:00 a.m. Central,Time. David Kaysen, President and ...
Cached Biology Technology:Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder 2Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder 3Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder 4Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder 5Ardea Biosciences Establishes Scientific Advisory Board for HIV Program 2Ardea Biosciences Establishes Scientific Advisory Board for HIV Program 3Ardea Biosciences Establishes Scientific Advisory Board for HIV Program 4
(Date:12/11/2014)... Dec. 10, 2014  That blood pressure plays a role ... Hypertension – the medical term for high blood pressure – ... and the inflatable cuff that,s used in measuring blood pressure ... there,s nothing new about hypertension, its triggers and its effects. ... the condition and the best ways to treat it. ...
(Date:12/10/2014)... 2014  Valencell, a leader in performance biometric data ... demand from its licensees for highly accurate, clinically validated ... solely coming from fitness and health sectors, but first ... wearable is only as useful as the biometric data ... driver in long-term mass consumer adoption of wearable products," ...
(Date:12/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ... "Biometrics Market in Japan 2014-2018" report to ... The integration of biometrics and ... and upgradation of the driver,s license is one ... Besides the aforementioned projects, biometrics is being used ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... new study seeks to determine how one parasitic species can ... The human body louse ( Pediculus humanus ) can transmit ... (also Pediculus humanus ) does not. A report ... Molecular Biology . "Body louse-transmitted diseases include trench fever, ...
... authors describe how in laboratory tests, they compared the ... stress by several antioxidants, some of which are found ... sunburn, UVA radiation penetrates deeper, damaging our DNA by ... skin its elastic quality. The Newcastle team found ...
... New research co-written by University of Montana scientists finds ... 31 large carnivore species. The analysis, published Jan. 9 in ... species including tiger, lion, dingo and puma are ... and John J. Craighead Chair and Professor of Wildlife Conservation ...
Cached Biology News:1 species, 2 outcomes: Team seeks source of body louse pathology 2Fresh faced: Looking younger for longer 2Fresh faced: Looking younger for longer 3Study shows large carnivore numbers and range declining worldwide 2
Immunogen for A300-655A was a phosphorylated synthetic peptide, which represented a portion of human RNA Polymerase II (GeneID 5430) around serine 5 of the C-terminal repeat YSPTSPS....
Acetylcholinesterase from human and monkey....
Excellent safety and durability., Remote control can be easily operated in your hand., Constant voltage control with 2 sets of terminals., Precise and durable circuit design. ...
... systems. , Integrated Instrument Control , ... EZChrom Elite can be configured with a ... provides a completely integrated system to control instrument's operation, collect andstore ... ...
Biology Products: